Literature DB >> 10898980

Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI.

S A Marsters1, M Yan, R M Pitti, P E Haas, V M Dixit, A Ashkenazi.   

Abstract

BLyS (also called TALL-1, THANK, or BAFF) [1] [2] [3] [4] is a member of the tumor necrosis factor (TNF) gene family that stimulates proliferation and immunoglobulin production by B cells. BLyS interacts with the TNF receptor (TNFR) homologue TACI (transmembrane activator and CAML-interactor) [5], and treatment of mice with a TACI-Fc fusion protein abolishes germinal center formation after antigenic challenge [6]. Here we report a novel interaction between BLyS and another TNFR homologue, BCMA (B cell maturation antigen) [7] [8]. Further, the TNF homologue APRIL [9], a close relative of BLyS, also bound to BCMA and TACI. BLyS or APRIL activated nuclear factor-kappaB (NF-kappaB) through TACI and BCMA, and each ligand stimulated immunoglobulin M (IgM) production by peripheral blood B cells. These results define a dual ligand-receptor system that may play an important role in humoral immunity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10898980     DOI: 10.1016/s0960-9822(00)00566-2

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  91 in total

Review 1.  Specific deletion of autoreactive T cells by adenovirus-transfected, Fas ligand-producing antigen-presenting cells.

Authors:  Huang-Ge Zhan; John D Mountz; Martin Fleck; Tong Zhou; Hui-Chen Hsu
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses.

Authors:  S Xu; K P Lam
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

Review 3.  T lymphocyte dependence of the antibody response to 'T lymphocyte independent type 2' antigens.

Authors:  A Jeurissen; J L Ceuppens; X Bossuyt
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

4.  Impaired IgA class switching in APRIL-deficient mice.

Authors:  Emanuela Castigli; Sumi Scott; Fatma Dedeoglu; Paul Bryce; Haifa Jabara; Atul K Bhan; Emiko Mizoguchi; Raif S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-26       Impact factor: 11.205

Review 5.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

6.  Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization.

Authors:  Hiroshi Okano; Katsuya Shiraki; Yutaka Yamanaka; Hidekazu Inoue; Tomoyuki Kawakita; Yukiko Saitou; Yumi Yamaguchi; Naoyuki Enokimura; Keiichi Ito; Norihiko Yamamoto; Kazushi Sugimoto; Kazumoto Murata; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

Review 7.  B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases.

Authors:  William Stohl
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

Review 8.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

9.  Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.

Authors:  Kodandaram Pillarisetti; Gordon Powers; Leopoldo Luistro; Alexander Babich; Eric Baldwin; Yingzhe Li; Xiaochun Zhang; Mark Mendonça; Nate Majewski; Rupesh Nanjunda; Diana Chin; Kathryn Packman; Yusri Elsayed; Ricardo Attar; François Gaudet
Journal:  Blood Adv       Date:  2020-09-22

10.  BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

Authors:  Jérôme Moreaux; Eric Legouffe; Eric Jourdan; Philippe Quittet; Thierry Rème; Cécile Lugagne; Philippe Moine; Jean-François Rossi; Bernard Klein; Karin Tarte
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.